Rebecca Miksad, MD

Associate Professor, Hematology & Oncology

Rebecca Miksad
617.638.7011
820 Harrison Avenue

Biography

Rebecca Miksad is a medical oncologist and health outcomes researcher who serves as senior medical director at Flatiron Health. In this role, Rebecca focuses on generating real-world evidence, establishing regulatory-grade quality standards and contributing to the development of clinically-relevant methods to real-world data evaluation and analyses.

Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally.

Prior to joining Flatiron Health, Rebecca was an assistant professor at Harvard Medical School, senior scientist at the Institute for Technology Assessment at Massachusetts General Hospital, and director of gastrointestinal oncology and gastrointestinal oncology clinical trials at Beth Israel Deaconess Medical Center (BIDMC). Rebecca’s academic research focused on improving cancer treatment decision-making through better characterization of patient outcomes and increasing relevance of clinical trial endpoints. Rebecca earned a BA cum laude in economics from Harvard University and an MD with honors in research from Cornell University. She was a resident in internal medicine at Cornell University/New York-Presbyterian Hospital, and completed hematology and medical oncology fellowships at Harvard Medical School/BIDMC. Rebecca earned a MMS from Harvard Medical School and an MPH in Clinical Effectiveness from the Harvard School of Public Health in clinical effectiveness (with an emphasis on decision science). She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).

Publications

  • Published on 6/1/2020

    Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2020 Jun 01; 3(6):e207205. PMID: 32511721.

    Read at: PubMed
  • Published on 4/18/2020

    Stinchcombe TE, Miksad RA, Gossai A, Griffith SD, Torres AZ. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression. Clin Lung Cancer. 2020 Apr 18. PMID: 32409266.

    Read at: PubMed
  • Published on 4/15/2020

    Aggarwal H, Sheffield KM, Li L, Lenis D, Sorg R, Barzi A, Miksad R. Primary tumor location and survival in colorectal cancer: A retrospective cohort study. World J Gastrointest Oncol. 2020 Apr 15; 12(4):405-423. PMID: 32368319.

    Read at: PubMed
  • Published on 2/13/2020

    Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, Schrag D, Miksad RA. Author's Response to "A Letter in Support of Real-World RECIST". Adv Ther. 2020 04; 37(4):1691-1693. PMID: 32056085.

    Read at: PubMed
  • Published on 2/1/2020

    Barzi A, Miksad R, Surinach A, Corvino FA, Wang S, Torres AZ, Mamlouk K, Pulgar S, Valderrama A, Bekaii-Saab T, Ahn D. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas. 2020 02; 49(2):193-200. PMID: 32011529.

    Read at: PubMed
  • Published on 12/8/2019

    Balogh EP, Bindman AB, Eckhardt SG, Halabi S, Harvey RD, Jaiyesimi I, Miksad R, Moses HL, Nass SJ, Schilsky RL, Sun S, Torrente JM, Warren KE. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 Mar; 25(3):e405-e411. PMID: 32162805.

    Read at: PubMed
  • Published on 12/4/2019

    Miksad R, Cicin I, Chen Y, Klumpen H, Kim S, Lin Z, Youkstetter J, Sen S, Cheng A, Meyer T, Kelley R, Abou-Alfa G. Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ann Oncol. 2019 Jul; 30 Suppl 4:iv134. PMID: 32085040.

    Read at: PubMed
  • Published on 12/4/2019

    Balogh EP, Bindman AB, Eckhardt SG, Halabi S, Harvey RD, Jaiyesimi I, Miksad R, Moses HL, Nass SJ, Schilsky RL, Sun S, Torrente JM, Warren KE. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2019 Dec 04. PMID: 31801899.

    Read at: PubMed
  • Published on 8/13/2019

    Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer. 2019 Aug 13; 19(1):795. PMID: 31409405.

    Read at: PubMed
  • Published on 8/5/2019

    Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer. 2019 Nov 15; 125(22):4019-4032. PMID: 31381142.

    Read at: PubMed

View 60 more publications: View full profile at BUMC

View all profiles